•
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement from the National Medical Products Administration (NMPA) to market its malignant stenosis cryoablation system in China. This innovative technology represents a significant advancement in the treatment of malignant airway tumors. Innovative Cryoablation TechnologyThe malignant stenosis…
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and…
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced a strategic distribution agreement with the Shanghai subsidiary of US medical device giant Boston Scientific Corporation (NYSE: BSX). As per the terms of the agreement, Cryofocus is set to become the exclusive marketing partner and…
•
Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its cryotherapy equipment, which supports its innovative frozen adhesion treatment system. The cryotherapy equipment comprises a main unit, a foot switch, and an exhaust pipe, and…
•
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced that it has received marketing approvals from China’s National Medical Products Administration (NMPA) for all components of its cardiac cryoablation system. The approvals include the cryoablation equipment, balloon type cryoablation catheter (previously known as the…